Savara to Advance Bronchiectasis Therapy Apulmiq After Deal With Grifols

Savara to Advance Bronchiectasis Therapy Apulmiq After Deal With Grifols
Savara Pharmaceuticals has acquired global rights to develop and commercialize Grifols' inhaled antibiotic formulation Apulmiq (ciprofloxacin) for the treatment for non-cystic fibrosis bronchiectasis (NCFB).

The agreement comes a couple of months after Grifols acquired Apulmiq and any related intellectual property from Aradigm, which originally developed Apulmiq but recently filed for bankruptcy.

Savara will now work with the U.S. Food and Drug Administration (FDA) to design the confirmatory Phase 3 trial required by the regulatory agency for Apulmiq's approval. "We are very excited about Apulmiq and believe it represents a transformational addition to our pipeline,” Rob Neville, Savara’s CEO, said in a press release. “Acquiring the rights provides us with another high potential Phase 3 program that leverages our core capabilities in inhaled orphan drug development and complements our existing pipeline." Added James Chalmers, PhD, chair of EMBARC, the European Bronchiectasis
Subscribe or log in to read the rest of this content.